Industry Symposia

INDUSTRY SYMPOSIA PROGRAM (FRIDAY, MARCH 31, 2023)

Time	Session

13:00 14:00	Advancing care in acute and chronic kidney patients Organized by Baxter Healthcare Watanyu Parapiboon Chairperson watanyu.kr@cpird.in.thMaharat Nakhonratchasima HospitalThailand Welcome and introductions Watanyu Parapiboon Speaker watanyu.kr@cpird.in.thMaharat Nakhonratchasima HospitalThailand A personalised start to life on dialysis: advantages of PD Edwina Brown Speaker e.a.brown@imperial.ac.ukHammersmith HospitalUnited Kingdom Value of CRRT: When, Why & How? Nattachai Srisawat Speaker drnattachai@yahoo.comChulalongkorn University, King Chulalongkorn Memorial HospitalThailand Panel discussion and Q and A Ballroom 1	The Evolving Treatment Landscape in IgA Nephropathy: A Case-Based Discussion Organized by Travere Therapeutics Muh Geot Wong Chairperson muhgeot.wong@sydney.edu.auUniversity of SydneyAustralia IgA nephropathy: A Deep Dive into The Treatment Landscape Muh Geot Wong Speaker muhgeot.wong@sydney.edu.auUniversity of SydneyAustralia Panel discussion: Evolving Landscape in IgA Nephropathy Patient Management Muh Geot Wong Speaker muhgeot.wong@sydney.edu.auUniversity of SydneyAustralia Sian Griffin Speaker svgriffin@googlemail.com Vivekanand Jha Speaker vjha@georgeinstitute.org.inThe George Institute for Global HealthIndia MR 109 ABFE	SGLT2 inhibitors: A driving force to improved standard-of-care in CKD Organized by Science Collected. Supported by an unrestricted educational grant from AstraZeneca Carol Pollock Chairperson carol.pollock@sydney.edu.auUniversity of SydneyAustralia Welcome and Introductions Carol Pollock Speaker carol.pollock@sydney.edu.auUniversity of SydneyAustralia Three-pronged protection Sydney Tang Speaker scwtang@hkucc.hku.hkThe University of Hong KongHong Kong, China Old problems, new solutions Carol Pollock Speaker carol.pollock@sydney.edu.auUniversity of SydneyAustralia Is it too late? An opportunity to intervene early Mustafa Arici Speaker marici@hacettepe.edu.tr Panel discussion and Q and A Closing remarks Carol Pollock Speaker carol.pollock@sydney.edu.auUniversity of SydneyAustralia MR 109 CDHG	Chinook Therapeutics: Changing the Course of Kidney Care Organized by Chinook Therapeutics Adrian Liew Chairperson draliew2@gmail.comMount Elizabeth Novena HospitalSingapore Atrasentan for the Treatment of IgA Nephropathy: Interim Results from the AFFINITY Study Adrian Liew Speaker draliew2@gmail.comMount Elizabeth Novena HospitalSingapore Updated Interim Results of a Phase 1 / 2 Study of BION-1301 in Patients with IgA Nephropathy Hernan Trimarchi Speaker htrimarchi@hotmail.comHOSPITAL BRITANICO DE BUENOS AIRESArgentina MR 110	C3G and IC-MPGN: Current state of evidence and how to tackle challenges in clinical management Organized by Novartis Edwin Wong Speaker eksw@doctors.org.uk Masashi Mizuno Speaker mmizu@med.nagoya-u.ac.jp Welcome and introduction Diagnostic challenges of C3G and IC-MPGN Marina Vivarelli Speaker marina.vivarelli@opbg.net Treatment approaches in C3G and IC-MPGN: Today and tomorrow Edwin Wong Speaker eksw@doctors.org.uk Q and A Closing Remarks Edwin Wong and Masashi Mizuno MR 111	Evolving Landscape in IgA Nephropathy Patient Management Organized by Calliditas Therapeutics Jonathan Barratt Chairperson jb81@leicester.ac.uk Welcome and Introductions Jonathan Barratt Speaker jb81@leicester.ac.uk Perspectives on Why IgA Nephropathy is a Mucosal Auto-immune Disease Yusuke Suzuki Speaker yusuke@juntendo.ac.jpJuntendo University School of MedicineJapan Evolving Considerations of Recent Advances in IgA Nephropathy Management See Cheng YEO Speaker see_cheng_yeo@ttsh.com.sg Updates on Emerging Therapies in IgA Nephropathy eGFR vs. Proteinuria Jonathan Barratt Speaker jb81@leicester.ac.uk Panel Q and A: Evolving Landscape in IgA Nephropathy Patient Management Plenary Hall 1
17:00 18:00	Evidence Based Treatment of Anemia in CKD: Focus on HIF-PHIs Organized by Zydus Lifesciences Brief overview - Anemia in CKD Sanjeev GULATI Speaker sgulati2002@gmail.co Managing Anemia in CKD with HIF PHIs - What Does Recent Evidence Tell Us? Dinesh Khullar Speaker drdineshkhullar@gmail.com Panel discussion: The Way Forward for HIF PHIs - Evidence to Clinical Practice Vijay Kher Moderator kherv1968@gmail.com Anil Bhalla Panelist bhallaak@yahoo.com Ashwani Gupta Panelist ashwani_gupta2002@yahoo.com Dibya Singh Shah Panelist dibyasingh@hotmail.comInstitute of Medicine ,Tribhuvan University Teaching HospitalNepal Dilip Kumar Pahari Panelist dilipkpahari@gmail.com Manisha Sahay Panelist drmanishasahay@gmail.comOsmania General HospitalIndia Narayan Prasad Panelist npsecretaryisnindia@gmail.comSanjay Gandhi Post Graduate Institute of Medical SIndia Prem Varma Panelist varmapp123@rediffmail.com Raj Kumar Sharma Panelist rksnepho206@gmail.com Urmila Anandh Panelist uanandh@gmail.comAmrita HospitalsIndia MR 109 ABFE		Optimizing Nutritional Therapy with Ketoanalogues in CKD Patients Organized by Fresenius Kabi Giorgina Barbara Piccoli Chairperson GBPICCOLI@YAHOO.IT Hallmarks of Nutritional Strategies to Delay Dialysis in CKD Patients Kamyar Kalantar-Zade Speaker kamyar@dispostable.com Clinical Role of Ketoanalogues: Real-world Evidences and Perspectives Maiszu WU Speaker angela@shinhotravel.com How to Implement Supplemented Protein- restricted Diets in Clinical Practice Giorgina Barbara Piccoli Speaker GBPICCOLI@YAHOO.IT Q and A MR 109 CDHG		Developments Into Expanding the Understanding of Anemia in CKD Supported by GSK Roberto Pecoits Filho Chairperson roberto.pecoits@arborresearch.orgArbor Research Collaborative for HealthUnited States About ISN iNET-CKD Maarten Taal Speaker maarten.taal1@nhs.net Results from the international variation in Hb study Adeera Levin Speaker alevin@providencehealth.bc.caUniversity of British ColumbiaCanada New study into longitudinal changes in Hb Maarten Taal Speaker maarten.taal1@nhs.net Q and A Closing remarks Maarten Taal Speaker maarten.taal1@nhs.net MR 111